Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price raised by The Goldman Sachs Group from $29.00 to $33.00 in a report published on Friday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on AGIO. JPMorgan Chase & Co. lowered their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a neutral rating for the company in a report on Friday, February 23rd. Cantor Fitzgerald restated an overweight rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Royal Bank of Canada cut their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform rating on the stock in a research note on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $35.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $34.54 on Friday. The company has a market cap of $1.96 billion, a PE ratio of -5.47 and a beta of 0.81. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $35.50. The stock’s 50 day simple moving average is $30.61 and its two-hundred day simple moving average is $25.68.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating the consensus estimate of ($1.64) by $0.19. The firm had revenue of $8.19 million for the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The company’s revenue for the quarter was up 46.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.47) EPS. Equities research analysts expect that Agios Pharmaceuticals will post -5.27 EPS for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,791 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the completion of the sale, the director now directly owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Agios Pharmaceuticals news, insider James William Burns sold 2,642 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total transaction of $86,049.94. Following the transaction, the insider now directly owns 34,518 shares in the company, valued at approximately $1,124,251.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now directly owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The disclosure for this sale can be found here. Insiders have sold 16,035 shares of company stock valued at $475,277 in the last 90 days. Company insiders own 4.24% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. SG Americas Securities LLC purchased a new stake in Agios Pharmaceuticals in the third quarter worth about $607,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Agios Pharmaceuticals by 25.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 2,148 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 1.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,497 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 689 shares during the period. Inspire Investing LLC boosted its stake in shares of Agios Pharmaceuticals by 12.0% during the third quarter. Inspire Investing LLC now owns 12,344 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 1,327 shares in the last quarter. Finally, TD Asset Management Inc increased its holdings in Agios Pharmaceuticals by 90.1% during the third quarter. TD Asset Management Inc now owns 92,218 shares of the biopharmaceutical company’s stock valued at $2,282,000 after buying an additional 43,719 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.